Metastatic Ewing sarcoma to the heart simulating adriamycin cardiotoxicity

Area of Science:

• Oncology
• Cardiology
• Pathology

Background:

• Ewing sarcoma is a rare bone cancer often treated with Adriamycin (doxorubicin).
• Adriamycin is known to cause cardiotoxicity, a potential side effect impacting heart function.
• Congestive heart failure is a serious condition requiring accurate diagnosis for effective treatment.

Observation:

• A 20-year-old male patient with metastatic Ewing sarcoma presented with severe congestive heart failure.
• Initial diagnosis considered Adriamycin cardiotoxicity due to the patient's treatment history.
• Autopsy revealed extensive cardiac metastases as the primary cause of heart failure.

Findings:

• Post-mortem examination showed no evidence of Adriamycin-induced cardiotoxicity.
• Massive cardiac infiltration by Ewing sarcoma was identified as the cause of heart failure.
• The patient's heart failure was directly attributed to metastatic disease, not chemotherapy side effects.

Implications:

• Cardiac metastases should be a key consideration in the differential diagnosis of heart failure in patients with metastatic cancer.
• This case underscores the need for thorough diagnostic evaluation beyond expected treatment toxicities.
• Accurate identification of heart failure etiology is crucial for appropriate patient management and treatment strategies.